Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425571 | 0.92 | RXFP1 (0.36) | HTR3ASMN1; SMN2LMNATP53RXFP1 | |
| SCHEMBL13634870 | 0.86 | SMN1; SMN2 (0.45) | HTR3ASMN1; SMN2LMNATP53RXFP1 | |
| SCHEMBL4425764 | 0.82 | TP53 (0.45) | SMN1; SMN2LMNATP53RXFP1MAPT | |
| SCHEMBL2069707 | 0.71 | PDK2 (0.41) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL23609272 | 0.71 | STAT5B (0.46) | LMNAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL18721166 | 0.69 | KCNQ4 (0.43) | GRM2 | |
| SCHEMBL15156657 | 0.69 | NR1D1 (0.43) | LMNAMAPTALDH1A1GRM2MEN1 | |
| SCHEMBL14525736 | 0.67 | ALDH1A1 (0.42) | HTR3ASMN1; SMN2LMNATP53RXFP1 | |
| SCHEMBL3063916 | 0.65 | KCNQ4 (0.43) | GRM2 | |
| SCHEMBL27657927 | 0.65 | ERCC1 (0.41) | HTR3ASMN1; SMN2LMNATP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1668002-A4 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-7109332-B2 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1668002-A2 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005032488-A2 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PFKP, DPP3, P2RY13 | HTR3A 423/4885SMN1; SMN2 4038/4885LMNA 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.